Hui Hao-Shen - Concepedia

Author

Hui Hao-Shen

University Hospital of Basel

Also Known As

H. Hao-Shen, Hao-Shen Hui, Hui Hao-Shen

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Basel University of Basel Novartis (Switzerland)Novartis Institutes for BioMedical Research SIB Swiss Institute of Bioinformatics

About

Hui Hao-Shen is an author at University Hospital of Basel specializing in cell signaling, signal transduction, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	122
2	Cell Biology	1	1	122
3	Immunology	1	1	122
4	Cell Development	1	1	122
5	Cell Signaling	1	1	122

Hui Hao-Shen

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms Pontus Lundberg, Axel Karow, Ronny Nienhold, Blood	2014	633
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Ralph Tiedt, Hui Hao-Shen, Marta Sobas, Blood	2007	430
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo Ralph Tiedt, Tibor Schomber, Hui Hao-Shen, Blood	2006	409
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms Franz X. Schaub, Renate Looser, Sai Li, Blood	2010	173
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms Simona Stivala, Tamara Codilupi, Šime Brkić, Journal of Clinical Investigation ImmunologyMyeloproliferative NeoplasmsCell DeathTumor BiologyMyeloid Neoplasia	2019	122
Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis Takafumi Shimizu, Lucia Kubovčáková, Ronny Nienhold, The Journal of Experimental Medicine	2016	113
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing <i>JAK2</i> -V617F Pontus Lundberg, Hitoshi Takizawa, Lucia Kubovčáková, The Journal of Experimental Medicine	2014	99
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms Tata Nageswara Rao, Nils Hansen, Julian Hilfiker, Blood	2019	77
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F Franz X. Schaub, Roland Jäger, Renate Looser, Blood	2008	70
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm Shivam Rai, Élodie Grockowiak, Nils Hansen, Nature Communications	2022	66

Page 1